PURPOSE:Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. PATIENTS AND METHODS: Patients with metastatic melanoma were prospectively assigned to receive unselected young TILs versus CD8(+)-enriched TILs. All patients received lymphodepleting chemotherapy and high-dose IL-2 therapy and were assessed for response, toxicity, survival, and immunologic end points. RESULTS:Thirty-four patients received unselected young TILs with a median of 8.0% CD4(+) lymphocytes, and 35 patients received CD8(+)-enriched TILs with a median of 0.3% CD4(+) lymphocytes. One month after TIL infusion, patients who received CD8(+)-enriched TILs had significantly fewer CD4(+) peripheral blood lymphocytes (P = .01). Twelve patients responded to therapy with unselected young TILs (according to Response Evaluation Criteria in Solid Tumors [RECIST]), and seven patients responded to CD8(+)-enriched TILs (35% v 20%; not significant). Retrospective studies showed a significant association between response to treatment and interferon gamma secretion by the infused TILs in response to autologous tumor (P = .04), and in the subgroup of patients who received TILs from subcutaneous tumors, eight of 15 patients receiving unselected young TILs responded but none of eight patients receiving CD8(+)-enriched TILs responded. CONCLUSION: A randomized selection design trial was feasible for improving individualized TIL therapy. Since the evidence indicates that CD8(+)-enriched TILs are not more potent therapeutically and they are more laborious to prepare, future studies should focus on unselected young TILs.
RCT Entities:
PURPOSE: Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. PATIENTS AND METHODS: Patients with metastatic melanoma were prospectively assigned to receive unselected young TILs versus CD8(+)-enriched TILs. All patients received lymphodepleting chemotherapy and high-dose IL-2 therapy and were assessed for response, toxicity, survival, and immunologic end points. RESULTS: Thirty-four patients received unselected young TILs with a median of 8.0% CD4(+) lymphocytes, and 35 patients received CD8(+)-enriched TILs with a median of 0.3% CD4(+) lymphocytes. One month after TIL infusion, patients who received CD8(+)-enriched TILs had significantly fewer CD4(+) peripheral blood lymphocytes (P = .01). Twelve patients responded to therapy with unselected young TILs (according to Response Evaluation Criteria in Solid Tumors [RECIST]), and seven patients responded to CD8(+)-enriched TILs (35% v 20%; not significant). Retrospective studies showed a significant association between response to treatment and interferon gamma secretion by the infused TILs in response to autologous tumor (P = .04), and in the subgroup of patients who received TILs from subcutaneous tumors, eight of 15 patients receiving unselected young TILs responded but none of eight patients receiving CD8(+)-enriched TILs responded. CONCLUSION: A randomized selection design trial was feasible for improving individualized TIL therapy. Since the evidence indicates that CD8(+)-enriched TILs are not more potent therapeutically and they are more laborious to prepare, future studies should focus on unselected young TILs.
Authors: Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531
Authors: Peter A Prieto; Katherine H Durflinger; John R Wunderlich; Steven A Rosenberg; Mark E Dudley Journal: J Immunother Date: 2010-06 Impact factor: 4.456
Authors: Stephanie L Goff; Franz O Smith; Jacob A Klapper; Richard Sherry; John R Wunderlich; Seth M Steinberg; Donald White; Steven A Rosenberg; Mark E Dudley; James C Yang Journal: J Immunother Date: 2010-10 Impact factor: 4.456
Authors: Kevin M Friedman; Peter A Prieto; Laura E Devillier; Colin A Gross; James C Yang; John R Wunderlich; Steven A Rosenberg; Mark E Dudley Journal: J Immunother Date: 2012-06 Impact factor: 4.456
Authors: Robert P T Somerville; Laura Devillier; Maria R Parkhurst; Steven A Rosenberg; Mark E Dudley Journal: J Transl Med Date: 2012-04-04 Impact factor: 5.531
Authors: Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg Journal: Clin Cancer Res Date: 2013-11-11 Impact factor: 12.531
Authors: Martina Sanlorenzo; Igor Vujic; Christian Posch; Akshay Dajee; Adam Yen; Sarasa Kim; Michelle Ashworth; Michael D Rosenblum; Alain Algazi; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Susanna Ortiz-Urda Journal: Cancer Biol Ther Date: 2014-03-20 Impact factor: 4.742
Authors: Mikko Siurala; Markus Vähä-Koskela; Riikka Havunen; Siri Tähtinen; Simona Bramante; Suvi Parviainen; J Michael Mathis; Anna Kanerva; Akseli Hemminki Journal: Oncoimmunology Date: 2016-02-18 Impact factor: 8.110